A Pharmacovigilance Analysis of Daptomycin Use Based on CLSI Susceptible Dose-Dependent Category.
Ming M ZhangRyan W StevensJennifer L AdemaKristin C MaraAudrey N SchuetzAaron J TandeChristina G RiveraPublished in: Infectious diseases and therapy (2023)
High-dose daptomycin was not associated with increased laboratory abnormalities or adverse drug reactions compared to standard-dose daptomycin.